Artgen Biotech PJSC (MIC:ABIO) Total Equity: ₽813 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC Total Equity?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 Total Equity is ₽813 Mil as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

Artgen Biotech PJSC's total equity for the quarter that ended in Jun. 2023 was ₽813 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Artgen Biotech PJSC Total Equity Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Total Equity Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.75 370.73 415.00 460.56 570.26

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 450.54 460.56 486.86 570.26 813.16
MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Artgen Biotech PJSC's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=2044.564-1474.309
=570

Artgen Biotech PJSC's Total Equity for the quarter that ended in Jun. 2023 is calculated as

Total Equity=Total Assets(Q: Jun. 2023 )-Total Liabilities(Q: Jun. 2023 )
=2355.516-1542.353
=813

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₽813 Mil mean?
Artgen Biotech PJSC (MIC:ABIO) has a Total Equity of ₽813 Mil as of Jun. 2023. The total amount of equity as record on a company's balance sheet. View historical data for Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Total Equity too high?
Artgen Biotech PJSC's current Total Equity is ₽813 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Total Equity compare to VRTX and REGN?
Artgen Biotech PJSC's Total Equity of ₽813 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Total Equity is ₽813 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Total Equity of ₽813 Mil. The current Total Equity is ₽813 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Total Equity is ₽813 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price